Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6421
    -0.0004 (-0.07%)
     
  • OIL

    83.24
    +0.51 (+0.62%)
     
  • GOLD

    2,406.70
    +8.70 (+0.36%)
     
  • Bitcoin AUD

    100,355.70
    +1,469.22 (+1.49%)
     
  • CMC Crypto 200

    1,386.96
    +74.34 (+5.66%)
     
  • AUD/EUR

    0.6023
    -0.0008 (-0.13%)
     
  • AUD/NZD

    1.0893
    +0.0018 (+0.17%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     
  • FTSE

    7,895.85
    +18.80 (+0.24%)
     
  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     
  • DAX

    17,737.36
    -100.04 (-0.56%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Drugmaker Sanofi trying to get French workers to work longer hours

Sanofi is offering its animal health unit Merial in exchange for Boehringer's consumer health business plus 4.7 billion euros ($5.2 billion) in cash in exclusive negotiations between both companies

Sanofi has opened talks to get some of its French employees to work longer hours, but unions charged Wednesday the drugmaker which posted a net profit of over two billion euros doesn't have a competitiveness problem.

A Sanofi spokesman confirmed that the talks which opened last month are aimed at "maintaining the competitiveness of our French sites in a durable manner."

France several years ago gave companies under financial pressure greater flexibility to negotiate changes in working conditions, but union leaders at Sanofi questioned whether the company really faced a competitiveness problem.

A company document consulted by AFP said management aims to improve productivity by 20 to 25 percent at some of its French pharmaceutical manufacturing facilities to match those in eastern Europe.

ADVERTISEMENT

A CFDT trade union leader said management had talked about increasing working hours, cutting the number of days off, rearranging work patterns and requiring workers to carry out additional functions.

"They say there is a competitiveness problem but they haven't demonstrated it to us," said Patrick Rojo, a leader at CGT union.

In the first half of this year Sanofi increased its net profit by a quarter to 2.32 billion euros ($2.6 billion).

So far the plans concern 5,000 of Sanofi's 27,000 employees in France.

The company, which is the maker of the anti-blood clot drug Plavix, employs 110,000 people worldwide.